General
Preferred name
AVIBACTAM
Synonyms
NXL-104 ()
AVE-1330A ()
AVIBACTAM SODIUM ()
Avibactam (free acid) ()
Avibactam (sodium) ()
Avibactam (sodium hydrate) ()
NXL-104 (free acid) ()
NXL-104 (hydrate) ()
AVE-1330A, NXL104 ()
NXL104 ()
Nxl-104 free acid ()
Nxl 104 ()
Avibactam sodium salt ()
Avibactam (sodium salt) ()
P&D ID
PD016237
CAS
1192491-61-4
1192500-31-4
2938989-90-1
Tags
covalent binder
drug
available
Approved by
FDA
First approval
2015
Drug Status
approved
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION
AVYCAZ (ceftazidime-avibactam), in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Providencia stuartii, Enterobacter cloacae, Klebsiella oxytoca, and Pseudomonas aeruginosa in patients 18 years or older.; AVYCAZ is also indicated for the treatment of complicated urinary tract infections including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter koseri, Enterobacter aerogenes, Enterobacter cloacae, Citrobacter freundii, Proteus spp., and Pseudomonas aeruginosa in patients 18 years or older.
DESCRIPTION
Avibactam (NXL104) is non-β-lactam β-lactamase inhibitor . It has activity against class A and C serine β-lactamases, including Klebsiella pneumoniae carbapenemases.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
18
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CovBinderInPDB
CBR000750
CBR000755
CBR000764
CBR001271
CBR001273
CBR001276
CBR001415
CBR001416
CBR001417
CBR001418
CBR001538
CBR001539
CBR001540
CBR001553
CBR001554
CBR001555
CBR001556
CBR001609
CBR001610
CBR001625
CBR001628
CBR002088
CBR002286
CBR002287
CBR002288
CBR002289
CBR002290
CBR002291
CBR002292
CBR002293
CBR002294
CBR002295
CBR002297
CBR002298
CBR002299
CBR002300
CBR002304
CBR002305
CBR002519
CBR002521
CBR003220
CBR003390
CBR003741
CBR003742
CBR003974
CBR003975
CBR003976
CBR003977
CBR004953
CBR004966
CBR005088
CBR005525
CBR005526
CBR005688
CBR005689
CBR005690
CBR005838
CBR006109
CBR006373
CBR006767
CBR006850
CBR007271
CBR007273
CBR007274
CBR007275
CBR007276
CBR007277
CBR007278
CBR007279
CBR007280
CBR007281
CBR007388
CBR007525
CBR007581
CBR007582
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
NCATS Inxight Approved Drugs
Pandemic Response Box
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
54
Molecular Weight
265.04
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
0
cLogP
-1.53
TPSA
130.24
Fraction CSP3
0.71
Chiral centers
3.0
Largest ring
6.0
QED
0.6
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Anti-infection
Target
CTX-M-15
KPC-2 ??-lactamases
P99 ??-lactamases
TEM-1 ??-lactamases
??lactamase
antibiotic
Bacterial
Beta-lactamase
¦Â-Lactamase
Indication
intra-abdominal infections, urinary tract infections, pyelonephritis
MOA
beta lactamase inhibitor
Source data
